Clinical Trials

493 enrolled 23 charts 1 FDA

Breast Neoplasms

NCT04481113 2026-01-29

Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer

Phase 1 Completed

8 enrolled

Unilateral Breast Neoplasms

NCT05305924 2026-01-28

Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer

28 enrolled

Phase 1 Active not recruiting

ER-Positive Breast Cancer

NCT02057133 2026-01-26

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

198 enrolled

Phase 1 Active not recruiting

Breast Neoplasms

NCT02779751 2026-01-26

A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer

100 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05696626 2026-01-26

ELAINEIII

Phase 3 Recruiting

500 enrolled

Breast Neoplasms

NCT04964934 2026-01-16

SERENA-6

315 enrolled

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site

NCT05169567 2026-01-16

postMONARCH

368 enrolled 14 charts

Phase 2 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT06001762 2026-01-16

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

90 enrolled

Breast Neoplasms

NCT04584853 2026-01-14

POETIC-A

123 enrolled

Breast Cancer Female

NCT06169371 2026-01-14

BRE-09

Phase 4 Recruiting

50 enrolled

Phase 2 Active not recruiting

Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Breast Neoplasms

NCT05501704 2026-01-07

ETHAN - ET for Male BC

60 enrolled

Breast Neoplasms, Male

NCT07002177 2026-01-07

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

196 enrolled

Breast Neoplasms

NCT05563220 2026-01-06

ELEVATE

435 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07292207 2025-12-18

ARCHE

30 enrolled

Breast Neoplasms

NCT04603183 2025-12-12

ABIGAIL

Phase 2 Completed

162 enrolled

Breast Cancer Metastatic

NCT06409390 2025-12-04

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

15 enrolled

Breast Neoplasms

NCT06495164 2025-11-25

A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer

Active not recruiting

1 enrolled

Breast Neoplasms

NCT03284957 2025-11-24

AMEERA-1

Phase 1/2 Terminated

136 enrolled 60 charts

Breast Neoplasms

NCT05867251 2025-11-19

Study of AVZO-021 in Patients With Advanced Solid Tumors

430 enrolled

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06139107 2025-11-14

RADIANT: Pre-op Radiation With Abemaciclib and Letrozole

Phase 1 Recruiting

15 enrolled

Breast Neoplasms

NCT03979508 2025-11-12

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

Phase 2 Terminated

26 enrolled

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating, Fibrocystic Breast Disease, Triple Negative Breast Neoplasms

NCT03280563 2025-11-10

MORPHEUS HR+BC

Phase 1/2 Completed

144 enrolled 25 charts

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07191717 2025-11-10

Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial

42 enrolled

Anatomic Stage I Breast Cancer AJCC v8

NCT05608252 2025-10-29

VS-6766+Abema+Fulv in Met HR+/HER- BC

63 enrolled

Breast Neoplasms

NCT02107703 2025-10-21

MONARCH 2

669 enrolled 22 charts 1 FDA

Breast Neoplasms

NCT06062498 2025-10-20

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

174 enrolled